Drugmaker Novo Nordisk fourth-quarter profit lags forecast

The logo of Danish multinational pharmaceutical company Novo Nordisk is pictured on the facade of a production plant in Chartres, north-central France, April 21, 2016. REUTERS/Guillaume Souvant/Pool - Copyright POOL New(Reuters)

By Reuters

Published on 01/02/2019 - 08:04•Updated 25/04/2024 - 11:09

Comments

COPENHAGEN (Reuters) - Denmark's Novo Nordisk <NOVOb.CO> posted fourth-quarter operating profit below forecasts on Friday, and said it would submit its oral semaglutide drug, an important growth hope, for U.S. approval in the first quarter.

Novo, the world's top maker of diabetes drugs, posted a quarterly operating profit of 10.8 billion Danish crowns ($1.66 billion), below an average 11.3 billion crowns forecast in a Reuters poll of analysts..